LMD-05. Phase 1B Study of Avelumab and Whole Brain Radiotherapy (WBRT) in Patients with Leptomeningeal Disease (LMD): Preliminary Results

BACKGROUND: LMD has a dismal prognosis with median survivals of 8–10 weeks. Recently the first phase 2 trial of PD-1 inhibitor monotherapy in solid tumor LMD showed median overall survival (OS) 3.6 months. We aimed to determine the safety/efficacy of avelumab with WBRT in patients with LMD from soli...

Descripción completa

Detalles Bibliográficos
Autores principales: Pina, Yolanda, Chen, Ann, Arrington, John, Macaulay, Robert, Tran, Nam, Liu, James, Mokhtari, Sepideh, Li, Jiannong, Law, Vincent, Sahebjam, Solmaz, Ahmed, Kamran, Creelan, Ben, Gray, Jhanelle, Khushalani, Nikhil, Smalley, Inna, Smalley, Keiran, Vogelbaum, Michael, Yu, Michael, Forsyth, Peter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Supplement Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8351314/
http://dx.doi.org/10.1093/noajnl/vdab071.030

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8351314/
http://dx.doi.org/10.1093/noajnl/vdab071.030

Ejemplares similares